CNS delivery of therapeutic agents
US9283181B2 · kind B2 · utility
18Cited by
12References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 25, 2011 |
| Grant date | Mar 15, 2016 |
| Priority date | — |
| Expiry date | Jul 24, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y302/0105
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.